We have developed an ointment preparation consisting of silver and zinc oxide nanoparticles, which form the basis of the nanocomposition. This drug can reduce the healing time of the wound surface due to the inclusion of nanodispersed particles in the composition. Application of nanoparticles allows to reduce inflammatory process, to carry out disinfecting treatment of a wound surface from pathogenic microorganisms, and accordingly to create optimum conditions for reparative process. Nanocomposite preparation has many advantages over existing analogues without irritating and allergic effects. Due to the high adsorption capacity, it allows to accelerate the healing process of the damaged surface of the skin. Initial studies were conducted on laboratory rats at the age of 6 months with a close mass that was up to 250 g in accordance with international requirements for the use of laboratory animals. As a result of the experiment, a new ointment preparation based on silver and zinc oxide nanoparticles, which are active components of the nanocomposition, was obtained. The use of these components allowed to accelerate the process of reparative restoration of the skin with full recovery of the studied animals. As shown by the experience, the recovery rate on average accelerated by seven days, compared with similar drugs available on the pharmaceutical market.
As a result of the studies, it was found that the proposed drug based on toltrazuril, tinidazole and levamisole hydrochloride according to the average lethal oral dose in accordance with GOST 12.1.007–76 belongs to the fourth hazard class - low-hazard substances. To assess the acute toxicity of the drug, experimental and control groups of whites were formed. Wistar rats weighing 190.2±5.92 grams. To study the acute toxicity of the drug based on toltrazuril, tinidazole and levamisole hydrochloride, a suspension was prepared using the Polysorbate 80 emulsifier. The prepared suspension in different dosages was administered through an intragastric tube to experimental animals and an equal volume of physiological saline was administered to the control group of white rats. With the introduction of a drug based on toltrazuril, tinidazole and levamisole hydrochloride at a dose of 3745 mg/kg, the death of two rats was recorded, which is 20% of the experimental group No. 5. With the introduction of the drug at a dose of 5350 mg/kg, 5 dead animals or 50% of experimental group No. 8 were registered, and with the introduction of 6420 mg/kg - 10 dead laboratory animals, i.e. all animals of the experimental group No. 10. When registering the body weight of white rats of the experimental and control groups, no statistically significant differences were found in the indicators for the entire observation period. At the same time, it should be noted that in the groups of experimental laboratory animals in which the drug was tested at a dose of 3745 mg/kg to 5885 mg/kg, lower values of body weight gain were established in comparison with the control. The minimum tolerated dose was found to be 3210.0 mg/kg, LD16 - 3679.7 mg/kg, LD50 - 5029.0 mg/kg, LD84 - 6121.5 mg/kg, LD100 - 6420.0 mg/kg and SLD50 - ±406. The data obtained allow us to proceed to the study of subchronic toxicity and irritant action of the developed drug.
The purpose of the research is the study of pharmaco-toxicological properties of the Ornidazole- and Levamisole hydrochloride-based drug.Materials and methods. The pharmaco-toxicological properties of the Ornidazole- and Levamisole hydrochloride-based drug were studied in the premises of the Laboratory of Preclinical Studies, Faculty of Veterinary Medicine, Stavropol State Agrarian University. Acute and chronic toxicity, and irritant effect of the drug was studied under the Guidelines for Preclinical Studies of Drugs (2012). Hematological studies of laboratory animals were performed with an automatic hematological analyzer, and biochemical studies of the blood serum were done with an automatic biochemical analyzer.Results and discussion. It has been found that the Ornidazole- and Levamisole hydrochloride-based drug belongs to the Hazard Class 3 for the median lethal oral dose in accordance with GOST 12.1.007–76 as moderately hazardous substances; it does not have a pronounced subchronic toxicity or irritant effect. Multiple use of the active substance for 14 days does not cause significant changes in the clinical condition, or in hematological and biochemical profile of laboratory animals.
Diarrhea of newborn calves is a globally common disease that causes significant damage to livestock. Economic losses from diarrhea in young cattle are directly related to the cost of long-term treatment of animals and their mortality, as well as the projected decrease in productivity, which negatively affects the efficiency of maintaining the entire herd. Currently, it is an established fact that diarrhea of newborn calves has a polyethological nature, which has an interaction in pathogenesis between the calf’s body, enteropathogens and the technology of keeping animals. For the treatment of calves with diarrhea caused by enteropathogenic Escherichia coli, many methods and schemes using various antibiotics have been proposed. The need for fast and efficient treatment for acute diarrhea of calves in many cases leads to an empirical selection of the drug without taking into account the spectrum of its activity. This approach leads to the appearance and rapid spread of antibiotic resistant strains of microorganisms and as a result reduces the effectiveness of veterinary measures. The article presents the results of a study of the effect of a new complex drug containing stabilized silver particles, an immunostimulator and an antioxidant on the body of calves with diarrhea, as an alternative to the antibiotics. Studies were conducted on calves of the first week of life with a diagnosis of diarrhea, with enteropathogenic Escherichia coli confirmation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.